ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
25/111
Lu AG06466 - phase lb
Lu AG06466 (former ABX1431) is an inhibitor of the
monoacylglycerol lipase (MAGL) and selective modulator of the
endocannabinoid system. It works to reduce excessive
neurotransmission and neuroinflammation that are known
pathophysiological hallmarks for a range of psychiatric and
neurological disorders.
A phase lb study was initiated in September 2020 with the
purpose to investigate the effect of Lu AG06466 after multiple
doses in patients with PTSD (NCT04597450).
Additional phase Ib investigational studies were initiated in
fibromyalgia patients in June 2021 (NCT04974359), in multiple
sclerosis spasticity in September 2021 (NCT04990219), and in
focal epilepsy in September 2021 (NCT05081518).
Trials across these indications will assess a variety of common
and innovative biomarkers to develop tools to help guide further
late-stage development and will guide decision making for future
development.
Lu AF28996 - phase I
Lu AF28996 is a small molecule with agonistic properties
towards D1 and D2 receptors. Continuous D1 and D2 dopamine
receptor stimulation may play an important role in motor control
of Parkinson's disease patients.
A Phase 1b study was initiated in February 2020 on Lu
AF28996 with the purpose to investigate the safety and
tolerability as well as pharmacokinetics of Lu AF28996 in
patients with Parkinson's disease (NCT04291859).
NEUROINFLAMMATION / NEUROIMMUNOLOGY
With the October 2021 agreement with AprilBio, Lundbeck took
a significant leap forward in our neuroinflammation /
neuroimmunology discovery platform. Through the agreement,
we gained exclusive worldwide rights to APB-A1 (now Lu
AG22515), a phase-I-ready biotherapeutic for the treatment of
neuroimmune diseases.
Lu AG22515 is a novel and well-differentiated anti-CD40 ligand
(CD40L) antibody-like drug candidate. Modulating the
CD40L/CD40 interaction holds great promise for treatment of a
wide range of autoimmune-related CNS disorders.
PROTEIN AGGREGATION, FOLDING AND CLEARANCE
Lu AF82422 - phase II
Lu AF82422 is a monoclonal antibody (mAb) targeting the
pathological form of the protein alpha-synuclein that is believed
to play a pivotal role in the development and progression of
MSA, Parkinson's disease and other neurodegenerative
disorders.View entire presentation